- Home
- KZIA vs KTTA Comparison
KZIA vs KTTA Comparison
Compare KZIA & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- KTTA
- Stock Information
- Founded
- KZIA 1994
- KTTA 2020
- Country
- KZIA Australia
- KTTA United States
- Employees
- KZIA N/A
- KTTA N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- KTTA Health Care
- Exchange
- KZIA Nasdaq
- KTTA Nasdaq
- Market Cap
- KZIA 5.1M
- KTTA 5.5M
- IPO Year
- KZIA 1999
- KTTA 2021
- Fundamental
- Price
- KZIA $10.45
- KTTA $0.68
- Analyst Decision
- KZIA Strong Buy
- KTTA
- Analyst Count
- KZIA 2
- KTTA 0
- Target Price
- KZIA $14.00
- KTTA N/A
- AVG Volume (30 Days)
- KZIA 745.7K
- KTTA 142.8K
- Earning Date
- KZIA 07-22-2025
- KTTA 08-12-2025
- Dividend Yield
- KZIA N/A
- KTTA N/A
- EPS Growth
- KZIA N/A
- KTTA N/A
- EPS
- KZIA N/A
- KTTA N/A
- Revenue
- KZIA $1,549,158.00
- KTTA N/A
- Revenue This Year
- KZIA N/A
- KTTA N/A
- Revenue Next Year
- KZIA N/A
- KTTA N/A
- P/E Ratio
- KZIA N/A
- KTTA N/A
- Revenue Growth
- KZIA 248983.08
- KTTA N/A
- 52 Week Low
- KZIA $2.86
- KTTA $0.67
- 52 Week High
- KZIA $79.00
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- KZIA 72.75
- KTTA 32.67
- Support Level
- KZIA $5.86
- KTTA $0.67
- Resistance Level
- KZIA $7.20
- KTTA $0.77
- Average True Range (ATR)
- KZIA 1.17
- KTTA 0.04
- MACD
- KZIA 0.15
- KTTA 0.01
- Stochastic Oscillator
- KZIA 82.21
- KTTA 14.02
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).